Difference between revisions of "Cisplatin (Platinol)"
Jump to navigation
Jump to search
m |
m |
||
| Line 10: | Line 10: | ||
*[[Adrenocortical carcinoma]] | *[[Adrenocortical carcinoma]] | ||
*[[Anal cancer]] | *[[Anal cancer]] | ||
| − | |||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| Line 18: | Line 17: | ||
*[[Cutaneous basal cell carcinoma]] | *[[Cutaneous basal cell carcinoma]] | ||
*[[Cutaneous squamous cell carcinoma]] | *[[Cutaneous squamous cell carcinoma]] | ||
| − | |||
*[[Endometrial cancer]] | *[[Endometrial cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
**[[Esophageal adenocarcinoma]] | **[[Esophageal adenocarcinoma]] | ||
**[[Esophageal squamous cell carcinoma]] | **[[Esophageal squamous cell carcinoma]] | ||
| − | |||
*[[Gallbladder cancer]] | *[[Gallbladder cancer]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| Line 30: | Line 27: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Low-grade glioma]] | *[[Low-grade glioma]] | ||
| − | |||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Malignant pleural mesothelioma]] | *[[Malignant pleural mesothelioma]] | ||
| Line 36: | Line 32: | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
*[[Neuroblastoma]] | *[[Neuroblastoma]] | ||
| + | *Non-Hodgkin lymphoma | ||
| + | **[[Anaplastic large cell lymphoma]] | ||
| + | **[[Diffuse large B-cell lymphoma]] | ||
| + | **[[Extranodal NK- and T-cell lymphoma, nasal type]] | ||
| + | **[[Mantle cell lymphoma]] | ||
| + | **[[Peripheral T-cell lymphoma]] | ||
| + | **[[Primary mediastinal B-cell lymphoma]] | ||
| + | **[[Transformed lymphoma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
| Line 41: | Line 45: | ||
*[[Pancreatic cancer]] | *[[Pancreatic cancer]] | ||
*[[Penile cancer]] | *[[Penile cancer]] | ||
| − | |||
| − | |||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
| − | |||
*[[Upper tract urothelial carcinoma]] | *[[Upper tract urothelial carcinoma]] | ||
*[[Vulvar cancer]] | *[[Vulvar cancer]] | ||
Revision as of 11:14, 2 May 2022
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration <0.5 mg/mL)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adrenocortical carcinoma
- Anal cancer
- Bladder cancer
- Breast cancer
- Carcinoma of unknown primary
- Cervical cancer
- Cholangiocarcinoma
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Endometrial cancer
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Head and neck cancer
- Hepatoblastoma
- Hodgkin lymphoma
- Low-grade glioma
- Melanoma
- Malignant pleural mesothelioma
- Multiple myeloma
- Nasopharyngeal carcinoma
- Neuroblastoma
- Non-Hodgkin lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Pancreatic cancer
- Penile cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Upper tract urothelial carcinoma
- Vulvar cancer
Patient drug information
- Cisplatin (Platinol) package insert[1]
- Cisplatin (Platinol) patient drug information (Chemocare)[3]
- Cisplatin (Platinol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/19/1978: Initial FDA approval
- 9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
- 9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy.
- 9/2/2010: (earliest label available at Drugs@FDA) Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
Also known as
- Code name: NSC 119875
- Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abiplatin | Axiplat | Biocisplatinum | Bioplatino | Blastolem | Briplatin | Brisplatin | C-Platin |
| Ceplatin | Ciplatan | Ciplexal | Cis-GRY | Cismaplat | Cispatin | Cisplamerck | Cisplan |
| Cisplasol | Cisplatex | Cisplatine | Cisplatino | Cisplatyl | Cisteen | Citoplatino | Citosin |
| Cysplatyna | Cytoplatin | Docistin | Elvecis | Fauldcispla | Ifapla | Kemoplat | Lederplatin |
| Metaplatin | Neoplat | Neoplatin | Noveldexis | Oncoplatin AQ | Peyrone's Chloride | Peyrone's Salt | Placis |
| Plastistil | Platamin | Platamine | Platiblastin | Platicis | Platidiam | Platikem | Platil |
| Platimit | Platin | Platinex | Platinil | Platino II Filaxis | Platinol | Platinox | Platinoxan |
| Platiran | Platistil | Platistin | Platistine | Platosin | Randa | Romcis | Sicatem |
| Sinplatin | Sisplanil | Tecnoplatin | Tisplal | Unistin | |||
References
Categories:
- Drugs
- Intravenous medications
- Intracavitary medications
- Vesicant
- Irritant
- Platinum agents
- Alkylating agents
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gallbladder cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Hepatoblastoma medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Melanoma medications
- Malignant pleural mesothelioma medications
- Multiple myeloma medications
- Nasopharyngeal carcinoma medications
- Neuroblastoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Small cell lung cancer medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Upper tract urothelial carcinoma medications
- Vulvar cancer medications
- FDA approved in 1978
- WHO Essential Cancer Medicine